Search Catalog Peptides
닫기
Catalog Products for your R&D needs!
PEPTIDES
Generic Peptides
Our Generic Peptides
Tirzepatide, DMF registration planned for 2028| Cat # | |
|---|---|
| Introduction | Tirzepatide is a synthetic peptide-based dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. It is a modified incretin peptide designed to activate both GIP and GLP-1 receptor signaling pathways, which play important roles in glucose metabolism, insulin secretion, and energy homeostasis. By engaging GIP and GLP-1 receptors, tirzepatide modulates incretin-mediated signaling, enhances glucose-dependent insulin responses, regulates glucagon secretion, and influences metabolic pathways. Due to its dual receptor activity and optimized peptide structure, tirzepatide is widely used as a research tool for investigating incretin biology, metabolic regulation, receptor signaling, and peptide pharmacology. |
| Sequence | Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ |
| MW | 4813.45 g/mol |
| Reference | 1. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical development. Molecular Metabolism. 2018;18:3–14. 2. Frias JP, Nauck MA, Van J, et al. Efficacy and safety of tirzepatide versus dulaglutide in type 2 diabetes. New England Journal of Medicine. 2021;385:503–515. 3. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385:503–515. 4. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). The Lancet. 2021;398(10295):143–155. 5. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism. 2021;46:101102. |
| Fields of application | |
| Synonyms | Tirzepatide, LY3298176, LY-3298176, GIP/GLP-1 receptor dual agonist, Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1/GIP receptor agonist, Incretin mimetic peptide, Long-acting GIP/GLP-1 receptor agonist |
| Structure |
|